Key facts
- Helex’s last known valuation is $36.9M (Oct 2025).
- It has raised $6.6M; the latest was Seed Round ($3.5M) in Oct 2025.
- Notable investors include SOSV, IndieBio, New York Ventures, Fondation Botnar, BlueHill Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Helex
- ·The full record, as it builds
Funding rounds
No funding rounds for Helex are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Helex
Developer of first-in-class genomic medicines designed for renal indications, combining the promise of non-viral targeted delivery and genome editing for the kidney. The company's platform is powered by data-driven deep-learning modeling using high-throughput next-generation sequencing data derived from the gene editing technology, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) edits on human cell lines to give reliable predictions and validate them in-house, enabling clients to accelerate the CRISPR-based drug research and cell and gene therapies market by a renal franchise of precise and scalable therapeutics.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 23
- Website
- helex.bio/
- Ownership
- Privately Held (backing)
Helex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Helex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Helex in its N-PORT filings yet. We sweep new filings monthly.